Association between Polymorphisms of Vitamin D Receptor and Lung Cancer Susceptibility: Evidence from an Updated Meta-analysis
J Cancer 2019; 10(16):3639-3649. doi:10.7150/jca.33431
Meng Li1, Xinyu Liu1, Na Liu2, Tian Yang1, Puyu Shi1, Ruiqing He1, Mingwei Chen1
- The risk of 40 diseases at least double with poor Vitamin D Receptor as of July 2019
- Overview Lung cancer and vitamin D
- Liposomal Vitamin D cocktail targets some lung cancers – June 2018
Items in both categories Lung Cancer and Vitamin D Receptor are listed here:
- Lung Cancer risk increases if low Vitamin D, poor activation of Vitamin D Receptor which affects the CALB1 gene – June 2024
- Lung Cancer is up to 7 X more deadly if poor vitamin D genes – Oct 2021
- Lung Cancer more likely if poor Vitamin D Receptor – meta-analysis June 2019
- Effects of Resveratrol against Lung Cancer in mice – Nov 2017
- Lung Cancer patients were 2.4 times more likely to have a poor Vitamin D Receptor gene – July 2017
Vitamin D Receptor category with CANCER in the title (76 as of Feb 2022)
This list is automatically updated
Download the PDF from VitaminDWiki
Purpose: The aim of this meta-analysis was to investigate polymorphism of Bsm1, Apal, Taq1 and Cdx-2 in vitamin D receptor (VDR) associations in relation to lung cancer (LC) susceptibility.
Methods: 9 literatures were recruited into this meta-analysis from PubMed, PMC, Embase, Web of Science, Cochrane library and CNKI. STATA version 15.1 was used for statistical tests. The heterogeneity was tested using I2 statistics. According to the value of I2, the random-effect model (REM) or fixed-effect model (FEM) was selected to combine data from studies, respectively. Potential publication bias was evaluated by Egger's test. Sensitivity analysis was also performed to evaluate the stability and reliability in results.
Results: Decreased susceptibility of LC was found in all genetic models contrast in Bsm1 gene of VDR
| a vs. A: | OR = 0.62, | 95 % CI = 0.44-0.87; |
| aa vs. AA: | OR = 0.76, | 95 % CI = 0.60-0.96; |
| Aa vs. AA: | OR = 0.59, | 95 % CI = 0.39-0.88; |
| aa vs. AA+Aa: | OR = 0.80, | 95 % CI = 0.64-0.99; |
| Aa+aa vs. AA: | OR = 0.57, | 95 % CI = 0.37-0.86 |
The similar results were also found in partial genetic models of Taq1 (a vs. A: OR = 0.88, 95 % CI = 0.79-0.98; aa vs. AA+Aa: OR = 0.84, 95 % CI = 0.73-0.98) and Cdx-2 (Aa vs. AA: OR = 0.80, 95 % CI = 0.66-0.98; Aa+aa vs. AA: OR = 0.79, 95 % CI = 0.65-0.96). Likewise, significant correlation between Bsm1, Taq1 polymorphism and LC risk was detected among Asians. Cdx-2 polymorphism was considered as a protective factor in Caucasians, whereas no association of Apal polymorphism with LC risk was observed in Asians and Caucasians for all genetic models.
Conclusion: The results of this meta-analysis suggested that Bsm1, Taq1 and Cdx-2 polymorphism may contribute to lung cancer susceptibility, more studies need be conducted to confirm in the future.